NCT04681911
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients who have received more than 3 therapeutic regimens for metastatic breast cancer (MBC); Patients who have never received Herceptin/trastuzumab; Patients who have never received treatment for MBC
https://ClinicalTrials.gov/show/NCT04681911